Literature DB >> 4037902

Implantable infusion pump management of insulin resistant diabetes mellitus.

H Buchwald, E P Chute, F J Goldenberg, C R Hitchcock, B J Hoogwerf, J J Barbosa, W M Rupp, T D Rohde.   

Abstract

Diabetes mellitus with resistance to insulin administered subcutaneously or intramuscularly (DRIASM) is a rare and brittle form of Type I diabetes, found predominantly in young females and characterized by inadequate glycemic response to subcutaneous or intramuscular insulin administration. DRIASM leads to frequent ketoacidosis and obligatory hospitalization for administration of intravenous insulin. The use of a totally implantable infusion pump effected dramatic improvement in the treatment of five patients with this difficult form of diabetes. Frequency of clinical ketoacidosis was reduced from 37 episodes per year to 0.4 episodes per year (99%), and average in-hospital days per month were reduced from 20.8 days to 2.2 days (89%) with a mean follow-up period of 14.4 months. Cost savings were approximately +10,000 per patient month. Quality of life was greatly improved for these individuals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4037902      PMCID: PMC1250895          DOI: 10.1097/00000658-198509000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

Review 1.  Fatal diabetic ketoacidosis: major causes and approaches to their prevention.

Authors:  R S Clements; B Vourganti
Journal:  Diabetes Care       Date:  1978 Sep-Oct       Impact factor: 19.112

2.  A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design.

Authors:  P J Blackshear; F D Dorman; P L Blackshear; R L Varco; H Buchwald
Journal:  Surg Forum       Date:  1970

3.  Aprotinin and insulin resistance.

Authors:  J C Pickup; R W Bilous; H Keen
Journal:  Lancet       Date:  1980-07-12       Impact factor: 79.321

4.  Resistance against subcutaneous insulin successfully managed with aprotinin.

Authors:  W A Müller; C Taillens; S Léreret; M Berger; J Philippe; P A Halban; R E Offord
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

5.  Defective absorption of injected insulin.

Authors: 
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

6.  The design and initial testing of an implantable infusion pump.

Authors:  P J Blackshear; F D Dorman; P L Blackshear; R L Varco; H Buchwald
Journal:  Surg Gynecol Obstet       Date:  1972-01

7.  Insulin resistance caused by massive degradation of subcutaneous insulin.

Authors:  E P Paulsen; J W Courtney; W C Duckworth
Journal:  Diabetes       Date:  1979-07       Impact factor: 9.461

8.  Apparent insulin resistance due to abnormal enzymatic insulin degradation: a new mechanism for insulin resistance.

Authors:  A McElduff; C J Eastman; S P Haynes; K M Bowen
Journal:  Aust N Z J Med       Date:  1980-02

9.  Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis.

Authors:  H Buchwald; T D Rohde; P D Schneider; R L Varco; P J Blackshear
Journal:  Surgery       Date:  1980-10       Impact factor: 3.982

10.  Low-dose insulin infusions in diabetic patients with high insulin requirements.

Authors:  P Dandona; M Foster; F Healey; E Greenbury; A G Beckett
Journal:  Lancet       Date:  1978-08-05       Impact factor: 79.321

View more
  3 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.

Authors:  Georg Biesenbach; Peter Grafinger; Andreas Raml
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

3.  USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION.

Authors:  Swashti Agarwal; Meenal Gupta; Sheila Gunn
Journal:  AACE Clin Case Rep       Date:  2019-04-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.